Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin

References

• Cho NH , Shaw JE , Karuranga S , et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract . 2018;138:271–281. doi:10.1016/j.diabres.2018.02.023 29496507
   PubMed Web of Science ®Google Scholar
• Rawshani A , Rawshani A , Franzén S , et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med . 2017;376(15):1407–1418. doi:10.1056/NEJMoa1608664 28402770
   PubMed Web of Science ®Google Scholar
• McGuire DK , Gore MO , Masoudi FA . Diabetes and heart failure in patients with coronary disease: separating markers from mediators. Diabetes Care . 2010;33(9):2120–2122. doi:10.2337/dc10-1123 20805283
   PubMed Web of Science ®Google Scholar
• Rao Kondapally Seshasai S , Kaptoge S , Thompson A , et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med . 2011;364(9):829–841. doi:10.1056/NEJMoa1008862 21366474
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358(24):2545–2559. doi:10.1056/NEJMoa0802743.18539917
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med . 2008;358(24):2560–2572. doi:10.1056/NEJMoa0802987.18539916
   PubMed Web of Science ®Google Scholar
• Matthews DR , Tsapas A . Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. Diabetes Vasc Dis Res . 2008;5(3):216–218. doi:10.3132/dvdr.2008.036
   PubMed Web of Science ®Google Scholar
• Tsapas A , Matthews DR . N of 1 trials in diabetes: making individual therapeutic decisions. Diabetologia . 2008;51(6):921–925. doi:10.1007/s00125-008-0983-2 18389212
   PubMed Web of Science ®Google Scholar
• Palmer SC , Mavridis D , Nicolucci A , et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. JAMA . 2016;316(3):313. doi:10.1001/jama.2016.9400 27434443
   PubMed Web of Science ®Google Scholar
• Zheng SL , Roddick AJ , Aghar-Jaffar R , et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes. JAMA . 2018;319(15):1580. doi:10.1001/jama.2018.3024 29677303
   PubMed Web of Science ®Google Scholar
• Bakris GL , Fonseca VA , Sharma K , Wright EM . Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int . 2009;75(12):1272–1277. doi:10.1038/ki.2009.87 19357717
   PubMed Web of Science ®Google Scholar
• Garcia-Ropero A , Badimon JJ , Santos-Gallego CG . The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol . 2018;14(12):1287–1302. doi:10.1080/17425255.2018.1551877 30463454
   PubMed Web of Science ®Google Scholar
• Madaan T , Akhtar M , Najmi AK . Sodium glucose CoTransporter 2 (SGLT2) inhibitors: current status and future perspective. Eur J Pharm Sci . 2016;93:244–252. doi:10.1016/j.ejps.2016.08.025 27531551
   PubMed Web of Science ®Google Scholar
• Zinman B , Wanner C , Lachin JM , et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med . 2015;373(22):2117–2128. doi:10.1056/NEJMoa1504720 26378978
   PubMed Web of Science ®Google Scholar
• Neal B , Perkovic V , Mahaffey KW , et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med . 2017;377(7):644–657. doi:10.1056/NEJMoa1611925 28605608
   PubMed Web of Science ®Google Scholar
• Wiviott SD , Raz I , Bonaca MP , et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med . 2019;380(4):347–357. doi:10.1056/NEJMoa1812389 30415602
   PubMed Web of Science ®Google Scholar
• McMurray JJV , Solomon SD , Inzucchi SE , et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med . 2019;381:1995–2008. doi:10.1056/NEJMoa1911303 31535829
   PubMed Web of Science ®Google Scholar
• Zhang M , Zhang L , Wu B , Song H , An Z , Li S . Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev . 2014;30(3):204–221. doi:10.1002/dmrr.2479 24115369
   PubMed Web of Science ®Google Scholar
• Wiviott SD , Raz I , Bonaca MP , et al. The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE)–TIMI 58 Trial. Am Heart J . 2018;200:83–89. doi:10.1016/j.ahj.2018.01.012 29898853
   PubMed Web of Science ®Google Scholar
• Kato ET , Silverman MG , Mosenzon O , et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation . 2019;139(22):2528–2536. doi:10.1161/CIRCULATIONAHA.119.040130 30882238
   PubMed Web of Science ®Google Scholar
• Furtado RHM , Bonaca MP , Raz I , et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation . 2019;139(22):2516–2527. doi:10.1161/CIRCULATIONAHA.119.039996 30882239
   PubMed Web of Science ®Google Scholar
• Mosenzon O , Wiviott SD , Cahn A , et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol . 2019;7(8):606–617. doi:10.1016/S2213-8587(19)30180-9 31196815
   PubMed Web of Science ®Google Scholar
• Nassif ME , Windsor S , Tang F , et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation . 2019;140(18):1463–1476. doi:10.1161/CIRCULATIONAHA.119.042929 31524498
   PubMed Web of Science ®Google Scholar
• Fioretto P , Del Prato S , Buse JB , et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE Study. Diabetes Obes Metab . 2018;20(11):2532–2540. doi:10.1111/dom.13413 29888547
   PubMed Web of Science ®Google Scholar
• Petrykiv S , Sjöström CD , Greasley PJ , Xu J , Persson F , Heerspink HJL . Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol . 2017;12(5):751–759. doi:10.2215/CJN.10180916 28302903
   PubMed Web of Science ®Google Scholar
• Sonesson C , Johansson PA , Johnsson E , Gause-Nilsson I . Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol . 2016;15(1):37. doi:10.1186/s12933-016-0356-y 26895767
   PubMed Web of Science ®Google Scholar
• Guo M , Ding J , Li J , et al. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab . 2018;20(8):1977–1982. doi:10.1111/dom.13295 29573118
   PubMed Web of Science ®Google Scholar
• Vasilakou D , Karagiannis T , Athanasiadou E , et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med . 2013;159(4):262–274. doi:10.7326/0003-4819-159-4-201308200-00007 24026259
   PubMed Web of Science ®Google Scholar
• Zelniker TA , Wiviott SD , Raz I , et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet . 2019;393(10166):31–39. doi:10.1016/S0140-6736(18)32590-X 30424892
   PubMed Web of Science ®Google Scholar
• Norhammar A , Bodegård J , Nyström T , Thuresson M , Nathanson D , Eriksson JW . Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: a nationwide observational study. Diabetes Obes Metab . 2019;21(5):1136–1145. doi:10.1111/dom.13627 30609272
   PubMed Web of Science ®Google Scholar
• Birkeland KI , Jørgensen ME , Carstensen B , et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol . 2017;5(9):709–717. doi:10.1016/S2213-8587(17)30258-9 28781064
   PubMed Web of Science ®Google Scholar
• Jabbour S , Seufert J , Scheen A , Bailey CJ , Karup C , Langkilde AM . Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab . 2018;20(3):620–628. doi:10.1111/dom.13124 28950419
   PubMed Web of Science ®Google Scholar
• Forxiga, INN-dapagliflozin - European Medicines Agency. Available from: https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf. Accessed 4 26, 2019.
   Google Scholar
• Davies MJ , D’Alessio DA , Fradkin J , et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care . 2018;41(12):2669–2701. doi:10.2337/dci18-0033 30291106
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2019 [web annotation]. Diabetes Care . 2019;42(Suppl.1):S90–S102.30559235
   PubMed Web of Science ®Google Scholar
• Farxiga approved in the US to reduce the risk of hospitalisation for heart failure in patients with type-2 diabetes. Available from: https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2019/farxiga-approved-in-the-us-to-reduce-the-risk-of-hospitalisation-for-heart-failure-in-patients-with-type-2-diabetes-21102019.html. Accessed 10 22, 2019.
   Google Scholar
• Cosentino F , Grant PJ , Aboyans V , et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J . 2019. doi:10.1093/eurheartj/ehz486
   Web of Science ®Google Scholar
• Lytvyn Y , Bjornstad P , Udell JA , Lovshin JA , Cherney DZI . Sodium glucose cotransporter-2 inhibition in heart failure. Circulation . 2017;136(17):1643–1658. doi:10.1161/CIRCULATIONAHA.117.030012 29061576
   PubMed Web of Science ®Google Scholar
• Zelniker TA , Braunwald E . Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in Diabetes. J Am Coll Cardiol . 2018;72(15):1845–1855. doi:10.1016/j.jacc.2018.06.040 30075873
   PubMed Web of Science ®Google Scholar
• DETERMINE-reduced - dapagliflozin effect on exercise capacity using a 6-minute walk test in patients with heart failure with reduced ejection fraction. Available from: https://clinicaltrials.gov/ct2/show/NCT03877237. Accessed 5 8, 2019.
   Google Scholar
• Effect of dapagliflozin plus low dose pioglitazone on hospitalization rate in patients with HF and HFpEF. Available from: https://clinicaltrials.gov/ct2/show/NCT03794518. Accessed 5 8, 2019.
   Google Scholar
• Dapagliflozin evaluation to improve the lives of patients with preserved ejection fraction heart failure. Available from: https://clinicaltrials.gov/ct2/show/NCT03619213. Accessed 5 8, 2019.
   Google Scholar
• DETERMINE-preserved - Dapagliflozin effect on exercise capacity using a 6-minute walk test in patients with heart failure with preserved ejection fraction. Available from: https://clinicaltrials.gov/ct2/show/NCT03877224. Accessed 5 8, 2019.
   Google Scholar
• Dapagliflozin in preserved ejection fraction heart failure. Available from: https://clinicaltrials.gov/ct2/show/NCT03030235. Accessed 5 8, 2019.
   Google Scholar
• Impact of dapagliflozin on diastolic dysfunction in type 2 diabetic patients. Available from: https://clinicaltrials.gov/ct2/show/NCT02751398. Accessed 5 8, 2019.
   Google Scholar
• A study to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease. Available from: https://clinicaltrials.gov/ct2/show/NCT03036150. Accessed 5 8, 2019.
   Google Scholar